Intrexon Corp (XON)

18.75
0.00 (0.00)
NYSE : Health Care
Prev Close 18.75
Open 18.66
Day Low/High 18.52 / 18.92
52 Wk Low/High 17.04 / 32.90
Volume 502.71K
Avg Volume 861.80K
Exchange NYSE
Shares Outstanding 120.52M
Market Cap 2.28B
EPS -1.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

First Week of April 2018 Options Trading For Intrexon (XON)

Investors in Intrexon Corp saw new options become available this week, for the April 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Oxitec's Friendly™ Aedes Mosquito Receives Positive Evaluation For European Standard In Relation To Human Health And The Environment

Oxitec's Friendly™ Aedes Mosquito Receives Positive Evaluation For European Standard In Relation To Human Health And The Environment

RIVM concludes negligible risk of Oxitec's Friendly™ Aedes mosquitoes

Arconic, Cedar Fair, Gilead: 'Mad Money' Lightning Round May 5 2017

Arconic, Cedar Fair, Gilead: 'Mad Money' Lightning Round May 5 2017

A roundup of Cramer's comments on stocks of interest to viewers.

Back to Earnings Next Week: Cramer's 'Mad Money' Recap (Friday 5/5/17)

Back to Earnings Next Week: Cramer's 'Mad Money' Recap (Friday 5/5/17)

With the Fed and the healthcare vote out of the way, markets will focus on earnings in the week ahead.

Good, the Bad and the Ugly; What Troubles Me: Doug Kass' Views

Good, the Bad and the Ugly; What Troubles Me: Doug Kass' Views

Doug Kass shares his thoughts on Facebook, Allergan and Eli Lilly.

Synthetic Biologics Reports Preclinical Data Demonstrating SYN-005 Provides Protection From Pertussis In Neonatal Animal Study

-- Study Results Further Support Advancement of SYN-005 into Clinical Trials for Treatment and Prevention of Pertussis --

Takeaways and Observations; The Good, the Bad and the Ugly: Doug Kass' Views

Takeaways and Observations; The Good, the Bad and the Ugly: Doug Kass' Views

Doug Kass shares his thoughts on Apple, Allergan and Western Digital.

Pfizer, Intrexon, Raytheon: 'Mad Money' Lightning Round

Pfizer, Intrexon, Raytheon: 'Mad Money' Lightning Round

Jim Cramer says Pfizer needs to do a deal and buy someone; and he thinks Raytheon is a terrific stock.

Twitter, Netflix, MetLife: Doug Kass' Views

Twitter, Netflix, MetLife: Doug Kass' Views

Doug Kass shares his thoughts on Twitter and talks about Sears.

Intrexon Creates Precigen, Inc. And Accelerates Strategic Review Of Structural Options Related To Health Assets

Geno Germano to Step Down as President; Randal Kirk to Remain CEO

Shell Deal Hands Biggest U.S. Oil Refinery to Saudi Aramco

Shell Deal Hands Biggest U.S. Oil Refinery to Saudi Aramco

Saudi Aramco will assume control of the biggest oil refinery in the U.S. after a $2.2 billion deal with Shell that exits a joint venture in Port Arthur, Texas.

XON: Insiders vs. Shorts

The most recent short interest data was recently released for the 01/31/2017 settlement date, and Intrexon Corp is one of the most shorted stocks of the Russell 3000, based on 11.99 "days to cover" versus the median component at 5.13. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

TheStreet Quant Rating: D (Sell)